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HLA Associations and Risk of Posttransplant
Lymphoproliferative Disorder in a Danish
Population-Based Cohort
Maja Ølholm Vase, MD,1 Eva Futtrup Maksten,2 Charlotte Strandhave, MD, PhD,3 Esben Søndergaard, MD, PhD,4
Knud Bendix, MD, PhD,5 Stephen Hamilton-Dutoit, MD, PhD,5 Claus Andersen, MD, PhD,6
Michael Boe Møller, MD, PhD,7 Søren Schwartz Sørensen, MD, PhD,8 Jan Kampmann, MD,9 Hans Eiskjær, MD,10
Martin Iversen, MD, PhD,11 Ilse Duus Weinreich,12 Bjarne Møller, MD, PhD,13 Bente Jespersen, MD, PhD,2
and Francesco d'Amore, MD, PhD1
Background. Posttransplant lymphoproliferative disorder (PTLD) is a feared complication to organ transplantation, associated
with substantial morbidity and inferior survival. Risk factors for PTLD include T cell–depleting induction therapy and primary infec-
tion or reactivation of Epstein-Barr virus. Possible associations between certain HLA types and the risk of developing PTLD have
been reported by other investigators; however, results are conflicting. Methods. We conducted a retrospective, population-
based study on 4295 Danish solid organ transplant patients from the Scandiatransplant database. Having identified 93 PTLD pa-
tients in the cohort, we investigated the association of HLA typeswith PTLD, Epstein-Barr virus status and time to PTLD onset. The
outcomes survival and PTLD were evaluated using Cox regression; mismatching, and the PTLD-specific mortality were evaluated
in a competing risk analysis. Results. Risk of PTLD was associated with male sex (odds ratio, 1.70; 95% confidence interval,
1.07-2.71), and, in women, HLA-DR13 conferred an increased risk (odds ratio, 3.22; 95% confidence interval, 1.41-7.31). In mul-
tivariate analysis, HLA-B45 and HLA-DR13 remained independent predictive factors of PTLD. Mismatching in the B locus was as-
sociatedwith a reduced risk of PTLD (P < 0.001). Overall survival was poor after a PTLDdiagnosis andwas significantly worse than
that in the remaining transplant cohort (P < 0.001).Conclusions.Our data indicate risk-modifying HLA associations, which can
be clinically useful after transplantation in personalized monitoring schemes. Given the strong linkage disequilibrium in the HLA re-
gion, the associations must be interpreted carefully. The large size, virtually complete ascertainment of cases and no loss to follow-
up remain important strengths of the study.
(Transplantation Direct 2015;1: e25; doi: 10.1097/TXD.0000000000000534. Published online 11 August.)
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The HLA genes are highly polymorphic, resulting ina wide variety of specificities in the peptide-binding
grooves. TheHLA specificities play a crucial role in infectious
and inflammatory conditions1 and have also been associated
with susceptibility to certain hematological diseases.2-4 Post-
transplant lymphoproliferative disorder (PTLD) is a feared
complication to organ transplantation, associated with sub-
stantial morbidity and inferior survival.5 Confirmed risk fac-
tors for PTLD include T cell–depleting induction therapy,
and primary infection or reactivation of Epstein-Barr virus
(EBV),6 underlining the importance of T-cell surveillance in
antitumor immune responses. Possible associations between
certain HLA types and the risk of developing PTLD have
been reported by other investigators.7-10 However, conflict-
ing results and short follow up (3-10 years) have made it dif-
ficult to draw firm conclusions with regard to the importance
of these associations. Because the incidence of EBV-negative
PTLD increases with follow-up, this might be an under-
reported group, and nonviral causes need also to be consid-
ered. With the increasing possibilities for monitoring and
preemptive treatment, information regarding risk factors,
even before transplantation, could be of considerable impor-
tance in the management of these patients.
METHODS
Study Population
This was a retrospective, population-based study includ-
ing all 4295 heart, kidney, heart-lung or lung solid organ
transplantations (SOTs) performed in Denmark during the
period January 1 1995, to Feb 19th 2013. Data were re-
corded in Scandiatransplant,11 which contains data on all
SOTs carried out in Denmark since 1995, including infor-
mation on HLA-typings of both donors and recipients. All
HLA typings were performed in laboratories in Copenhagen
and Aarhus, accredited by the “European Federation for
Immunogenetics” in accordance with current standards.
For MHC class I, HLA-A and -B, and for MHC class II,
HLA-DR were recorded. It was possible to determine the
killer immunoglobulin-like receptor ligand HLA-Bw4 and
HLA-Bw6 status in 3962 and in 3973 patients, respectively,
based on http://hla.alleles.org/antigens/bw46.html.
Cases of PTLD were identified in the Danish Scandia-
transplant cohort by combined retrieval of data from the
Danish Cancer Registry and the Danish Lymphoma Group
Registry. This strategy was applied to maximize capture of
incident lymphoma cases. The Danish Cancer Registry has re-
corded incident cancer cases on a nationwide scale since 1943
with accurate and almost complete ascertainment of cases.12
Lymphoma diagnoses were coded according to the Interna-
tional Classification of Diseases (ICD) for Oncology (ICD-
O-1-3) from 1977 to 2003 and according to ICD-10 since
2004. All cases recorded from 1978 onward have subse-
quently been converted to ICD-10 codes, including codes for
lymphoma subtypes. The PTLDs occurring up to 3months af-
ter graft loss, and subsequent tapering of immunosuppressive
therapy, were included. Patient status (alive or deceased) was
retrieved from the Danish civil registration registry, including
date if deceased. All data sources were linked using the
civil registration number, a unique 10-digit personal identifier
assigned at birth or immigration to all Danish residents since
1968. The number encodes sex and date of birth. It permits
valid and unambiguous linkage between all registries and clin-
ical databases in Denmark and ensures no loss to follow-up.
This initial strategy identified 88 PTLDs in the Danish
Scandiatransplant cohort. A further 5 PTLDs in patients
transplanted in the period 1990 to 1995, and in which ca-
ses, HLA data were available, were identified through the
participating pathology departments. Thus, a total of 93
PTLDs were included in the correlation analyses.
The histopathology of all cases of PTLD identified among
cohort members were reviewed by expert hematopathol-
ogists (coauthors K.B. or S.H.D.) and reclassified accord-
ing to current World Health Organization (WHO) 2008
criteria,13 provided a sufficient amount of tumor tissue was
available. In cases with inadequate tumor tissue (n = 41),
the original pathology reports and chart review unequivo-
cally confirmed the PTLD diagnosis.
Detailed clinical data were obtained from the Danish Lym-
phoma Group Registry and frommedical records. The study
was approved by the Central Denmark Region Committees
on Health Research Ethics (record no. 41309) and the Danish
Data Protection Agency (record no. 1-16-02-247-13) and was
conducted in accordance with the Helsinki Declaration.
Immunohistochemistry for Revision
of Tumor Classification
Primary diagnostic formalin fixed paraffin-embedded tis-
sue samples containing representative PTLD were available
from 52 patients; samples of these were included in a tissue
microarray (TMA). Briefly, three 1-mm diameter tissue
cores were identified in tumor areas, punched out and re-
embedded in recipient blocks using a TMA master-01
(3DHISTECH Ltd., Budapest, Hungary).
Immunohistochemical stains were performed on 4 μm for-
malin fixed paraffin-embedded tissue sections according to
standard antibody-specific protocols, optimized in house for
use with the Ventana Benchmark automated staining system
(Ventana Medical Systems, Tucson, AZ). For review of the
classification of the tumors according to WHO 2008 criteria,
a panel of markers was applied consisting of CD3 (poly-
clonal, Dako, Glostrup, Denmark), CD5 (SP19, VentanaMed-
ical Systems), CD4 (SP35, Ventana), CD8 (SP57, Ventana),
CD10 (SP67, Ventana), CD20 (L26, Ventana), CD79a
(MRQ-48, Ventana), CD30 (Ber-H2, Dako) and MUM1
(MUM1P, Dako). The EBV antigens were visualized using
antibodies to LMP (LMP clones CS.1-4, Dako) and EBNA2
(PE2; Abcam, Cambridge, UK). EBV-RNA (EBER) expres-
sion was identified by in-situ hybridization (ISH iView Blue
Detection kit; Ventana). In each case, EBV status in the PTLD
cell population was evaluated by the authors (S.H.D. and
M.V.) and recorded as either positive or negative.
HLA Supertypes
The class I major histocompatibility complex molecule
presents intracellularly derived peptides from protein process-
ing. Although these receptors are extremely polymorphic, class
I molecules can be clustered into 9 so-called supertypes that
bind largely overlapping peptide structures.14 In addition to
carrier frequencies, the HLA class I phenotypes were also cat-
egorized according to the deduced supertype.
Statistical Analyses
Associations between HLA typings, deduced HLA super-
types, EBV status and PTLDoccurrencewere evaluated using
2 Transplantation DIRECT ■ 2015 www.transplantationdirect.com
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logistic regression, and risk estimates presented as odds ratios
(OR). Time to PTLD was examined by linear regression after
log-transformation to obtain normal distribution of data.
Only HLA types constituting 1% or greater in our cohort
were included in the analyses. To adjust formultiple hypothesis
testing, the first Benjamini-Yekutieli method15 was applied
to control the false discovery rate within each HLA type
and adjusted P values (q values) were reported.
Outcomes were evaluated by performing Kaplan-Meier
time-to-event analyses and were compared using the log-
rank test or Wilcoxon test for nonproportional data. Overall
survival (OS) was calculated from time of diagnosis of PTLD
to death from any cause, and progression-free survival (PFS)
as time from first diagnosis to confirmed relapse, progression
or death from any cause. For both OS and PFS, patients were
censored at November 24, 2014. The PTLD-associated mor-
tality was evaluated in a competing risk model using a
pseudovalues method,16 and outcome was assessed by the
methods described by Pepe and Mori.17 Similarly, HLA
mismatching of donors and recipients and PTLD occurrence
were evaluated in a competing riskmodel with death without
PTLD and graft loss without PTLD as competing events; in
the analysis for EBV-positive PTLD, EBV-negative PTLD
was also considered a competing risk, and vice versa for
EBV-negative PTLD. Risk estimates at fixed timepoints were
calculated using the pseudovalues approach and expressed as
relative risk (RR) with 95% confidence intervals (95%CI).18
Cox proportional hazards regression analyses were employed
to evaluate independent prognostic factors for outcome. Var-
iables with P less than 0.10 in univariate analysis were en-
tered into the multivariate analysis as covariates.
Significance was defined as P less than 0.05, and all statisti-
cal analyses were performed using STATA IC 12 (StataCorp,
College Station, TX).
RESULTS
Clinicopathological Features of the Patients
The characteristics of the patients are summarized in
Table 1 (the subgroup of patients in the TMA has been de-
scribed previously19). Patients developing PTLD were trans-
planted at a significantly younger age (mean age 41 years vs
44 years; P = 0.018), and the majority (74%) were men.
Epstein-Barr virus was present in the tumor cell population
in 60 of 77 (78%) cases with known EBV status. Comparing
patients with EBV-negative and EBV-positive PTLDs, no sig-
nificant age differences were found at either the time of trans-
plantation or at the time of PTLD presentation. The median
time to PTLD was 2.2 (interquartile range, 0.8-5.9) and 7.2
(interquartile range, 2.4-9.1) years for EBV-positive and
EBV-negative PTLD, respectively (P = 0.011), and 3.3 years
(interquartile range, 1.0-7.7 years) for the combined PTLD
cohort. In the whole cohort, the median follow-up from
transplantation to censoring was 7.1 years (interquartile
range, 3.7-11.8 years) and did not differ between the patients
who developed PTLD and those who did not (P = 0.116).
Host-Related Risk Factors of PTLD
An overview of all HLA phenotype frequencies in trans-
planted patients is provided in Table S1 (SDC, http://links.
lww.com/TXD/A7). Comparing the PTLD cohort with the
rest of the transplanted patients, HLA-B45wasmore common
in PTLD patients (4.3% vs 1.4%).
The risk of developing PTLDwas strongly associated with
male sex (age-adjustedOR♀, 0.59; 95%CI, 0.37-0.93; OR♂,
1.71; 95% CI, 1.07-2.71; P = 0.040). This applied to all
HLA specificities and deduced supertypes. For women only,
HLA-DR6 and HLA-DR8 expression tended to correlate
with a higher risk (OR♀, 2.28; 95% CI, 1.02-5.14 and
TABLE 1.
Baseline characteristics of all transplantations
PTLD patients
N (%)
Transplantations without
PTLD N (%) P
Number 93 (100) 4202 (100)
Age at transplantation,
mean (range), y
41 (1-68) 44 (0.5-83) 0.018
Sex (%)
Male 68 (73) 2595 (62) 0.026
Female 25 (27) 1607 (38)
Organ transplant (%)
Kidney 72 (77) 3175 (75) 0.158
Heart 12 (13) 469 (11)
Lung 8 (9) 550 (13)
Heart and lung 1 (1) 8 (1)
Transplantation per calendar period (per year)
Before 1995 (not included
in rate calculation)
5 0 0.000
1995-1999 33 (6) 1045 (208)
2000-2004 26 (4.6) 1125 (225)
2005-2009 21 (4.0) 1160 (232)
2010-2013a 8 (2.5) 872 (277)
Induction therapy
Antithymocyte globulin 31 (33) 1367 (33) 0.638
CD25 antibody 39 (42) 1928 (46)
EBV serostatus
R−/D+ 10 (11) 66 (2) b
R+/D+ 3 (3) 566 (13)
Unknown 80 (86) 3570 (85)
Previous malignancy
Nonmelanoma skin cancer 13 (14) Unknown
Otherc 6 (6) Unknown
Histological subtype of PTLD
Early lesions 14 (15) NA
Polymorphic lesions 6 (7)
Monomorphic lesions 73 (78)
Diffuse large
B-cell lymphoma
58 (62)
Classical Hodgkin
lymphoma
5 (5)
Burkitt lymphoma 3 (3)
Marginal zone lymphoma 2 (2)
T-anaplastic large
cell lymphoma
2 (2)
Malignant lymphoma
unspecified
2 (2)
Mantle cell lymphoma 1 (1)
aCutoff at February 19, 2013.
bDue to large amount of missing data statistical analyses were regarded inappropriate.
c1 renal cell carcinoma, 2 prostate cancer, 1 melanoma, 1 carcinoid tumor, 1 ductal carcinoma of
the breast.
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OR♀, 3.20; 95% CI, 1.07-9.55), respectively, adjusted
P values were not significant). When looking at the splits of
HLA-DR6, this higher risk was solely attributable to the
HLA-DR13 split (OR♀, 3.22; 95% CI, 1.41-7.31; P =
0.045). Comparing the EBV-positive PTLD patients versus
patients without PTLD, an increased OR for carriers of the
split HLA-B45 (OR, 5.83; 95% CI, 2.25-15.10; P < 0.001)
was found. None of these phenotypes was associated with
EBV-negative PTLD. In the latter, only HLA-B57 (OR,
5.78; 95% CI, 1.62-20.54; P = 0.072) showed a trend to-
ward an increased risk. All estimates were adjusted for sex.
The relevant ORs are presented in Figure 1, and the sex-
specificORs inFigure S1 (SDC, http://links.lww.com/TXD/A7).
Differences in HLA Phenotypes Between EBV-Positive
and EBV-Negative PTLD
In the PTLD cohort, the EBV-positive lymphoprolife-
rations developed significantly earlier after transplantation
than the EBV-negative ones (see above). However, this effect
of EBV was influenced by the patient's HLA type. The pres-
ence of HLA-A2 and HLA-B15 were consistently associated
with a shorter time to PTLD onset for EBV-positive tumors
(P = 0.028 and 0.03, respectively); for the HLA types, A10,
A11, B14, B18, B21, and B22, the EBV-positive PTLD pre-
sented earlier regardless of whether the HLA type was
expressed or not (all P values, 0.011-0.037). In contrast, for
HLA-A1, -A3, -A9, -A19, -A28, -B5, -B7, -B8, -B13, -B16,
-B17, -B27, -B35, -B37, -B40, -DR2, -DR3, -DR5, -DR7,
-DR8, and -DR9, when present, the time to PTLD was not
associated with the EBV status of the tumor (all P values be-
tween 0.011 and 0.043). When examining the splits, the
results were consistent with those of the broad specificities,
except for HLA-B45[12], in which EBV-positive PTLD al-
ways had a shorter time to onset, no matter the expression
status (P = 0.015; group 2).
HLA Mismatching and Risk of PTLD
The implications of HLA mismatching on PTLD develop-
ment are depicted in Figure 2. At the HLA-B locus, zero mis-
matches were associated with a significantly higher incidence
of PTLD (P < 0.001) compared with 1 to 2 mismatches;
this corresponded to an RR for 1 to 2 mismatches at 5 and
10 years of 0.42 (95% CI, 0.23-0.75; P = 0.003) and 0.52
(95%CI, 0.31-0.86; P = 0.010), respectively. At 5 years after
transplantation, HLA-DR mismatching was associated with
a small, but statistically significant, risk reduction for EBV-
negative PTLD compared with no mismatches (RR, 0.07;
95% CI, 0.008-0.57; P = 0.013). The HLA-A mismatching
had no impact on PTLD incidence. The number of mis-
matches for both HLA-A and -B was significantly lower in
living donor transplantations (P < 0.001 for both). However,
donor type itself (i.e., living versus deceased) was not associ-
ated with PTLD occurrence (P = 0.525).
The risk of PTLD, as illustrated by the incidence rate, differed
according to time after transplantation and to the EBV status
of the tumor (Table S2, SDC, http://links.lww.com/TXD/A7).
The previously reported bimodal pattern20 is in our data
attributable to the variation in EBVexpression (Figure 3), with
PTLD cases from the first incidence peak developing soon
after transplantation being largely EBV positive, followed
over 15 to 20 years after transplantation by a rise in EBV-
negative PTLD.
Results of the univariate and multivariate analyses for risk
of developing PTLD are listed in Table 2. The individual var-
iables were chosen based on the results of the regression anal-
yses and predefined variables of interest. The multivariate
analysis was adjusted for sex, because of the observed sex-
related differences. Expression of HLA-B45–, HLA-DR13–,
and the HLA-A2–associated supertypes remained indepen-
dent predictive factors for the risk of developing PTLD
(Table 2).
FIGURE 1. Sex- and EBV-specific odds ratios for significant split specificities with regard to development of posttransplant lymphoprolifer-
ative disorder.
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Survival Analyses
With a mean follow-up of 4 years (range, 0-18 years) from
onset of PTLD, the 5-year OS and PFS, for all PTLD pa-
tients taken as 1 group, were 58% (95% CI, 47-68%) and
51% (95% CI, 38-58%), respectively (Figure 4). As ex-
pected, patients with monomorphic disease did consider-
ably worse than patients with early/polymorphic lesions
(log-rank P = 0.022). Also, mismatching at the DR locus
was associated with poorer survival (5-year OS, 70%
(45-85%), 62% (47-75%), and 29% (11-49%) for 0, 1, and
2 mismatches, respectively; log-rank P = 0.013).
The variables assessed at univariate level are listed in
Table 3. In the multivariate Cox regression analysis, we
included HLA-DR mismatches, rituximab treatment, WHO
performance status, nodal versus extranodal disease, and
Ann Arbor stage. All except HLA-DR mismatches retained
independent prognostic value in the multivariate analysis
(Table 3).
Next, we evaluated PTLD-specific mortality (Figure 4)
in the total cohort of transplanted patients. The PTLD pa-
tients had a significantly higher mortality compared with
the remaining cohort population, with a risk difference of
24% (95% CI, 15-33%) at 5 years and 49% (95% CI,
36-62%) at 10 years after transplantation (P < 0.001 for both
risk estimates).
DISCUSSION
In this large population-based cohort of Danish SOT pa-
tients, we identified several host-related risk factors for the
development of PTLD and performed outcome analyses in
various patient subsets.
We identified HLA types associated with PTLD according
to: time to PTLDonset, tumoral EBV status, sex and survival.
So far, the data on HLA typing related to the development of
PTLD is scarce and discordant.7-10 Three studies also in-
cluded a variety of organ transplantations from both living
and deceased donors in mainly white populations; Reshef
et al9 identified HLA-A26 as the main PTLD risk locus,
Subklewe et al7 reportedHLA-B18 and -B21 asmain risk fac-
tors, whereas Lustberg et al10 pointed to HLA-B40. In our
cohort, HLA-A26 was only found in 5% of the transplanted
patients and in 8% of those who developed PTLD. Corre-
sponding values for HLA-B21 were 4% and 2% in the 2
groups, respectively, whereas HLA-B18 was found in 6%
of patients in both groups. The HLA-B40 was also almost
equally expressed in control and PTLD patients. The fourth
study by Pourfarziani et al8 is markedly smaller, included
only renal transplantations, and reported data from an Ira-
nian patient cohort with an expectedly different immunolog-
ical background to our patients. The primary risk loci in our
study (HLA-B45 and -DR13) have never been reported be-
fore and remained independent predictive factors for the
risk of developing PTLD in multivariate analysis. They were
both identified in patient subgroups, and we did not iden-
tify any risk alleles in the combined cohort. These differ-
ences probably reflect the heterogeneity of the analyzed
patient cohorts and emphasize the need for a detailed
FIGURE 2. Donor-recipient HLAmismatches in PTLD development.
Graphs show the PTLD cumulative incidence function of HLA-A mis-
matches (A), HLA-B mismatches (B), and HLA-DR mismatches (C).
FIGURE 3. Incidence rates for PTLD according to EBV status of
the tumor.
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characterization of donor, recipient and tumor biology to fa-
cilitate cohort comparisons.
One of the strongest associations revealed by our study
was the significantly higher risk of PTLD in male patients.
The present report is one of the few to identify this associa-
tion, and is the first to link a sex-related risk to a specific
HLA phenotype. An increased risk related to male sex was
previously reported by Dharnidharka et al,21 Morton et al,22
and Lustberg et al10 and is consistent with the general male
preponderance also seen in lymphomas occurring in non-
overtly immunosuppressed individuals. The male prepon-
derance was found throughout all HLA phenotypes and
supertypes. Furthermore, our findings indicate a difference
in PTLD-associated HLA types in men and women, as is also
the case in chronic lymphocytic leukemia.2 Interestingly, 2 of
the disease-associated HLA types identified in this study
(HLA-B45 and HLA-DR13) play similar roles in the context
of EBV infection because they both present immediate-early
proteins (BRLF1 and BZLF1) expressed in the lytic cycle.23
These same proteins are also presented by HLA-B18, which
in a large cohort of diffuse large B-cell lymphomas corre-
lated significantly with outcome, and was associated with
PTLD.3,7 Moreover, in humans, viral peptide specific CD4+
T-cells play a crucial role in controlling both primary and
recurrent infections. It has been shown, that sex-specific
differences in memory T-cell responses exist,24-26 although
available data are limited, and an increased risk in menmight
be attributable to factors other than the HLA system. The in-
fluence of EBV on PTLD development is unquestionable;
however, the rate of EBV-negative PTLD increases with
follow-up. In our series, the latest observed case of PTLD oc-
curred 17 years after transplantation; the long follow-up
without loss of cases is one of themain strengths of this study.
It is unclear whether these “late occurring” EBV-negative
TABLE 2.
Cox regression analyses for PTLD development
Variables PTLD patients N (%)
Univariate Multivariatea
HR (95% CI) P HR (95% CI) P
Sex
Male 68 (73) ref 0.055
Female 25 (27) 0.64 (0.40-1.01)
Time covariates
Age at transplantation, mean(range) 47 (2-77) 0.99 (0.98-1.00) 0.240
HLA mismatches
A
0 25 (27) ref
1-2 68 (73) 0.94 (0.60-1.49) 0.801
B
0 23 (25) ref ref
1-2 70 (75) 0.57 (0.35-0.91) 0.018 0.61 (0.37-1.01) 0.055
DR
0 26 (28) ref
1-2 67 (72) 0.93 (0.59-1.46) 0.757
HLA carrier status
HLA-A2 41 (48) 0.71 (0.46-1.08) 0.108
HLA-B44 26 (30) 1.34 (0.85-2.12) 0.217
HLA-B45 4 (5) 3.62 (1.33-9.88) 0.012 3.52 (1.28-9.67) 0.015
HLA-DR13 20 (23) 1.57 (0.96-2.58) 0.072 1.70 (1.03-2.79) 0.037
Supertype A2 41 (48) 0.63 (0.41-0.96) 0.033 0.62 (0.40-0.95) 0.027
Donor type
Living 24 (26) ref
Deceased 66 (71) 1.18 (0.74-1.88) 0.489
Unknown 3 (3)
Organ transplantedb
Kidney 72 (77) ref
Heart 12 (13) 1.46 (0.76-2.79) 0.255
Lung 8 (9) 1.23 (0.55-2.73) 0.620
Heart-lung 1 (1) 6.32 (0.86-46.51) 0.070 4.87 (0.66-36.02) 0.212
Induction therapy
Antithymocyte globulin 31 (33) ref
CD25 antibody 39 (42) 1.26 (0.74-2.17) 0.396
Unknownc 23 (25)
a Adjusted for sex.
b Adjusted for transplant center.
c The group is formed of kidney transplantation, who all received induction.
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lymphomas represent sporadic disease, result from “hit and
run” EBV infection, or evolve after many years as the result
of the accumulated effect of various possible transplantation-
associated factors, such as chronic antigen stimulation by
the graft or long-term immunosuppressive medication. We
identified 1 HLA-allele (HLA-B45) associated with EBV-
positive lymphoproliferations, in line with the findings from
2 gene expression profiling studies, that suggest that PTLDs
segregate according to EBV status27,28 rather than histological
subtype. The differences between EBV-negative and EBV-
positive PTLDs based on tumoral EBV status were investi-
gated in 2 studies7,9; these identified differently associated
HLA types, although these did not overlap our results. A re-
cent study was not able to confirm these reported findings,29
despite using the largest EBV-positive cohort to date. Differ-
ences in EBV latency programs and varying tumor histology
(B-cell vs T-cell, indolent vs aggressive, polyclonal vs mono-
clonal) may explain this, as well as the inconsistent results.
In line with previous reports, we found the HLA-A2
supertype to be correlated with a lower occurrence of lym-
phoproliferation.4,30 HLA-A2 is capable of inducing effective
cytotoxic T-cell responses against EBV latent antigen pep-
tides in many individuals,23 thereby probably protecting
against reactivation. Interestingly,HLA-A2presents variousmi-
nor H antigens (mHags).31 In allogeneic hematopoietic stem
cell transplantation, mHag disparities increase the frequency
and strength of graft-versus-host and graft-versus-leukemia
effects. In a multicenter study, a significantly lower relapse
rate in patient/donor pairs mismatched for hematopoietic
mHags was demonstrated,32 and it is plausible that the cyto-
toxic T-cell response elicited by mHag mismatching trans-
lates into a more effective tumor control.
Our findings indicate a protective effect of mismatches in
the B-loci overall, and of DR-mismatches in EBV-negative
PTLD. Because the mechanisms of how HLA types are asso-
ciated to PTLD development are largely unknown, possible
explanations for the protective effect of HLA-B-locus mis-
matching against PTLD development remain speculative.
Roughly a quarter of our patients received a graft from a living
donor, some of which were related and thus possibly matched
for unknown antigens, which might have been of greater
importance in determining susceptibility to PTLD than the
possible impact of HLA type matching. Wong et al33 found a
similar association, although in lung transplant patients, and
attributed this observation to impaired tumor surveillance sec-
ondary to decreased alloreactivity in matched patients. Also in
this field, published results are conflicting. Thus, 2 large stud-
ies by Caillard et al34 and Faull et al,20 which also included
both deceased and living donors, found no associations be-
tween HLA mismatching and risk of PTLD. In contrast 3
other large studies35-37 reported increased risks of PTLDwith,
respectively, increasedHLA-DR-,HLA-B- and overall number
of mismatches. However, several factors make direct compar-
isons with our work difficult. The study by Opelz et al35 in-
cluded only deceased-donor transplantations and cases of
posttransplant non-Hodgkin lymphomas. In addition, their
follow-up was 3 years after transplantation, thus exclud-
ing most EBV-negative and a substantial proportion of the
EBV-positive PTLDs from their analysis. We also used a dif-
ferent methodology (a competing risk model) as the present
competing events would bias the Kaplan-Meier estimate.38
Similarly, the estimates in the study by Bakker et al36 are
not easy to interpret, as the authors included several variables
in a Cox regression model which counted 20 events.39
Caillard et al34 later reported no association with HLA mis-
matches. Although no definitive causal explanations can be
given, we find it likely that mismatching results in a more
vigorous immune response against donor-derived peptides,
thereby creating a less permissive tumor microenvironment.
Patient survival was poor after a diagnosis of PTLD, al-
though the introduction of treatment with the CD20 anti-
body rituximab has improved survival and also remained
an independent prognostic factor. Poor performance status
and widespread disease were also independently associated
with a dismal outcome, reflecting both aggressive disease
and probably also the frailty of the patients, which does not
allow for too aggressive treatment strategies. The impact of
HLAmismatching onOS is in line with previous reports.40-42
A major limitation of our study is the lack of information
on the immunosuppressive treatment used in the total cohort
after transplantation, because different regimens are associ-
ated with risk of PTLD.43 We did, however, adjust for trans-
plantation site in the Cox analysis to account for different
strategies at the various transplantation centers, and this
did not show any association with PTLD development. Also,
we had only scarce information on donor/recipient EBV
seromismatches at time of transplant, which might explain
some of the varying HLA associations in the literature, and
our results should be interpreted in the light of this. The large
FIGURE 4. Outcome. Progression-free survival, overall survival and
PTLD-related mortality. A, All PTLD patients. B, The PTLD-related
mortality compared with mortality in the remaining cohort of trans-
plant patients.
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TABLE 3.
Patient and PTLD characteristics with cox regression univariate and multivariate analyses for mortality
Variables Patients N (%)
Univariate Analyses Multivariate Analysis
HR (95% CI) P HR (95% CI) P
Sex
Male 68 (73) ref
Female 25 (27) 0.54 (0.24-1.12) 0.104
Time covariates
Time to PTLD, mean (range) 5 (0.25-17) 0.96 (0.90-1.03) 0.297
Year of transplantation (5-y intervals) 93 (100) 0.91 (0.69-1.20) 0.498
HLA mismatches
A 0 19 (22) ref
1 52 (60) 1.59 (0.70-3.62) 0.219
2 16 (18) 1.85 (0.67-5.12) 0.233
B 0 17 (20) ref
1 40 (46) 0.76 (0.32-1.77) 0.523
2 30 (34) 1.47 (0.66-3.28) 0.348
DR 0 20 (23) ref
1 47 (54) 1.01 (0.44-2.27) 0.994
2 20 (23) 2.57 (1.07-6.18) 0.035 2.40 (0.86-6.69) 0.094
HLA carrier status
HLA-A2 40 (47) 0.87 (0.46-1.65) 0.675
HLA-B44 26 (30) 1.25 (0.64-2.43) 0.513
HLA-B45 4 (5) 1.54e-15 (0) 1.0
HLA-DR13 20 (23) 0.82 (0.38-1.78) 0.614
Supertype A2 41 (48) 0.86 (0.46-1.64) 0.655
Supertype B44 45 (48) 0.79 (0.44-1.43) 0.438
Immunosuppressive treatment
Cyclosporin 69 (79) 1.78 (0.69-4.56) 0.230
Tacrolimus 35 (41) 0.59 (0.29-1.18) 0.136
MMF 65 (75) 0.72 (0.37-1.43) 0.351
Azathioprine 20 (24) 1.90 (0.96-3.79) 0.067
Induction therapya
Antithymocyte globulin 31 (33) ref
CD25 antibody 39 (42) 0.63 (0.27-1.50) 0.297
Presentation
Early (<1 y) 23 (25) ref
Late (>1 y) 70 (75) 1.11 (0.56-2.20) 0.762
Stage
I-II 54 (59) ref
III-IV 38 (41) 2.29 (1.26-4.16) 0.007 2.22 (1.31-4.36) 0.020
Primary localization
Nodal 43 (46) ref
Extranodal 50 (54) 2.23 (1.20-4.15) 0.012 2.57 (1.18-5.57) 0.017
WHO performance score
0-2 73 (81) ref
3-4 17 (19) 5.73 (2.96-11.07) 0.000 6.32 (3.00-13.35) 0.000
EBV status of tumor
Positive 60 (78) ref
Negative 17 (22) 0.88 (0.38-2.01) 0.753
Graft PTLD
Present 8 (9) 1.61 (0.68-3.84) 0.280
Absent 85 (91) ref
Type PTLD
Early/polymorphic lesion 20 (22) ref
Monomorphic PTLD 64 (78) 1.61 (1.05-2.47) 0.029
PTLD treatment
Rituximab 45 (49) 2.05 (1.09-3.85) 0.025 2.96 (1.48-5.93) 0.002
a Adjusted for organ transplanted.
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size, inclusion of both early and monomorphic lesions, virtu-
ally complete ascertainment of cases, and no loss to follow-
up remain important strengths of the study.
In conclusion, we report several risk-modifying HLA asso-
ciations, which can be clinically useful in personalized moni-
toring schemes after transplantation.
Given the strong linkage disequilibrium in the gene-
rich HLA region, each of the HLA associations has to be
interpreted carefully, as other strongly linked alleles might
actually represent the true causative variant, and other
non-HLA genes in the region might also be involved. Our
present data should therefore be supplemented and con-
firmed by more extensive genomic analyses, such as whole
genomic sequencing.
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